Loading...
Loading...
Indian Pharmaceutical Exporter Β· #8 for Exemestane Β· $200.0K export value Β· DGFT Verified
Cadila Healthcare Limited is the #8 Indian exporter of Exemestane with $200.0K in export value and 4 verified shipments. Cadila Healthcare Limited holds a 1.4% market share in Exemestane exports across 1 countries. The company exports 41 pharmaceutical products worth $34.9M across 17 therapeutic categories.

| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $4.2M | 83 | 37.3% |
| NETHERLANDS | $1.7M | 80 | 15.2% |
| UNITED KINGDOM | $1.4M | 27 | 12.1% |
| GERMANY | $882.2K | 25 | 7.9% |
| BRAZIL | $800.0K | 16 | 7.2% |
| MEXICO | $446.1K | 12 | 4.0% |
| HUNGARY | $400.0K | 8 | 3.6% |
| GREECE | $242.9K | 9 | 2.2% |
| AUSTRALIA | $224.2K | 13 | 2.0% |
| VENEZUELA | $215.1K | 7 | 1.9% |
India exports Exemestane to 57 countries. The top destination is UNITED STATES (37.3%), followed by NETHERLANDS and UNITED KINGDOM.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| CARDINAL HEALTH | UNITED STATES | $800.0K | 16 |
| BROCACEF NL HUB | NETHERLANDS | $699.9K | 20 |
| FIEGE HEALTHCARE LOGISTICS GMBH | GERMANY | $604.5K | 19 |
| AUROBINDO PHARMA USA., INC, | UNITED STATES | $450.0K | 9 |
| CIPLA USA INC UPS SUPPLY CHAIN SOLU | UNITED STATES | $450.0K | 9 |
India exported $10.9M worth of Exemestane through 1,533 shipments from 87 suppliers to 57 countries, serving 196 buyers globally. Cadila Healthcare Limited contributes $200.0K to this total, accounting for 1.4% of India's Exemestane exports.
Cadila Healthcare Limited's average Exemestane shipment value is $50.0K per consignment, based on 4 shipments totaling $200.0K.
Cadila Healthcare Limited ranks #8 among 87 Indian Exemestane exporters with a 1.4% market share. The top 3 exporters are INTAS PHARMACEUTICALS LIMITED ($4.5M), MSN LABORATORIES PRIVATE LIMITED ($1.7M), EUGIA PHARMA SPECIALITIES LIMITED ($1.4M). Cadila Healthcare Limited processed 4 shipments to 1 destination countries.
What Cadila Healthcare Limited must comply with to export Exemestane to its top destination countries
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10β18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Approval Process
Exporters ranked immediately above and below #8 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 9 | INTAS PHARMACEUTICALS LTD | $355.9K | 13 | 4 | $27.4K |
| 7 | ZYDUS LIFESCIENCES LIMITED | $300.0K | 6 | 1 | $50.0K |
| 8 | CADILA HEALTHCARE LIMITED β | $200.0K | 4 | 1 | $50.0K |
| 10 | JODAS EXPOIM PRIVATE LIMITED | $136.6K | 6 | 1 | $22.8K |
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 314 | 20.5% |
| DELHI AIR CARGO ACC (INDEL4) | 273 | 17.8% |
| SAHAR AIR | 256 | 16.7% |
| DELHI AIR | 128 | 8.3% |
| Bombay Air Cargo | 62 | 4.0% |
| MUNDRA SEA (INMUN1) | 52 | 3.4% |
| MUNDRA SEA | 51 | 3.3% |
| AHEMDABAD AIR ACC (INAMD4) | 50 | 3.3% |
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Zydus. The escalating conflict in the Middle East has disrupted key maritime routes, particularly the Red Sea and Suez Canal, leading to longer transit times and increased freight costs. Major carriers have suspended or restricted transits, extending transit times by 10β20 days and raising freight rates by 40β50% on key IndiaβEurope routes. (livemint.com) This situation poses significant challenges for time-sensitive pharmaceutical shipments, especially temperature-sensitive medicines. (economictimes.indiatimes.com)
Conversely, U.S.βChina trade tensions have prompted the U.S. to impose tariffs on Chinese pharmaceutical imports, creating an opportunity for Indian exporters to fill the supply gap. However, the U.S. has also introduced tariffs on Indian imports, including a 25% "reciprocal" tariff, followed by an additional 25% penalty tied to India's continued imports of Russian oil, bringing the total duty to 50%. (en.wikipedia.org) While pharmaceuticals are currently exempt, the potential for future tariffs necessitates strategic planning.
In the European Union, compliance with the Falsified Medicines Directive (FMD) is crucial. The FMD mandates stringent serialization and traceability requirements to prevent counterfeit medicines from entering the supply chain. Non-compliance can result in restricted market access, making adherence to these regulations imperative for exporters like Zydus.
Maintaining compliance with international regulatory standards is paramount for Indian pharmaceutical exporters. The U.S. FDA, WHO, and EU Good Manufacturing Practice (GMP) guidelines set stringent quality benchmarks. Any lapses can lead to import alerts, product recalls, or facility shutdowns. For instance, in 2019, Zydus's Moraiya facility received an Official Action Indicated (OAI) classification from the U.S. FDA, indicating that regulatory and/or administrative actions were recommended. (moneycontrol.com) Such events underscore the importance of robust quality assurance systems.
The evolving regulatory landscape demands continuous investment in compliance infrastructure. The EU's Falsified Medicines Directive and the U.S. Drug Supply Chain Security Act (DSCSA) require advanced serialization and traceability measures. Non-compliance can result in restricted market access, making adherence to these regulations imperative for exporters like Zydus.
Cadila Healthcare Limited exports 41 products worth $34.9M. Beyond Exemestane, top products include Carvedilol, Losartan, Spironolactone, Iron, Chloroquine. View the complete Cadila Healthcare Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Exemestane β including regulatory updates, trade policy changes, and competitive landscape analysis β will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records β the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cadila Healthcare Limited's Exemestane exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cadila Healthcare Limited
Full Company Profile β
41 products Β· $34.9M total trade Β· 17 categories
| XXDUSXXHARXXCEUXXCALXXUSAXXNC |
| UNITED STATES |
| $300.0K |
| 6 |
| ZYDUS PHARMACEUTICALS USA INC | UNITED STATES | $250.0K | 5 |
| M P L | UNITED KINGDOM | $200.0K | 4 |
| AUROBINDO PHARMA USA INC | UNITED STATES | $150.0K | 3 |
| AUROBINDO PHARMA USA., INC | UNITED STATES | $150.0K | 3 |
India's Exemestane is purchased by 196 buyers worldwide. The top buyer is CARDINAL HEALTH (UNITED STATES), followed by BROCACEF NL HUB and FIEGE HEALTHCARE LOGISTICS GMBH.
Post-Brexit UK Marketing Authorisation via national procedure. Separate from EU approval since January 2021.
Timeline: 12β15 months
GMP & Export Requirements
UK GMP compliance; MHRA inspection of manufacturing site
Manufacturer Import Authorisation (MIA) held by UK importer; Qualified Person (QP) batch release
Note: Post-Brexit: EU GMP certificates no longer automatically valid in UK. Separate MHRA recognition required.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
| 11 |
| CELON LABORATORIES PRIVATE LIMITED |
| $119.7K |
| 10 |
| 4 |
| $12.0K |
Cadila Healthcare Limited ranks #8 among 87 Indian Exemestane exporters. Average shipment value of $50.0K compared to the market average of $124.9K. The closest competitors by value are INTAS PHARMACEUTICALS LTD and ZYDUS LIFESCIENCES LIMITED.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 57+ countries, 196+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for Cadila Healthcare Limited.
Request DemoView Pricing βTrade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Exemestane. For current shipment-level data, contact TransData Nexus.